ReviewHematology. American Society of Hematology. Education Program2011
New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome.
Review in Hematology. American Society of Hematology. Education Program, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma.Cancer medicine · 2023Trial
- Old drugs, new challenges: reassigning drugs for cancer therapies.Cellular & molecular biology letters · 2025Review
- Development of the treatment preference in myelodysplasia questionnaire for clinicians, carers, and patients.EJHaem · 2024Article
- Emerging Epigenetic Targets and Their Molecular Impact on Vascular Remodeling in Pulmonary Hypertension.Cells · 2024Review
- Molecular Targeting and Rational Chemotherapy in Acute Myeloid Leukemia.Journal of experimental pharmacology · 2020Review
- Epigenetic regulation of gene expression in cancer: techniques, resources and analysis.Briefings in functional genomics · 2018Article
- The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2016Article
- CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Article
- Towards an understanding of the role of DNA methylation in rheumatoid arthritis: therapeutic and diagnostic implications.Therapeutic advances in musculoskeletal disease · 2015Review
- Stopping higher-risk myelodysplastic syndrome in its tracks.Current hematologic malignancy reports · 2014Review
- Current therapy of myelodysplastic syndromes.Blood reviews · 2013Review
- Epigenetic therapy of hematological malignancies: where are we now?Therapeutic advances in hematology · 2013Article
- Zebularine-induced apoptosis in Calu-6 lung cancer cells is influenced by ROS and GSH level changes.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Mechanisms of epigenetic regulation of leukemia onset and progression.Advances in immunology · 2013Review
- Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine.Haematologica · 2012Article
- Zebularine inhibits the growth of HeLa cervical cancer cells via cell cycle arrest and caspase-dependent apoptosis.Molecular biology reports · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Ongoing analysis of the seminal AZA-001 study has taught many important lessons in the use of DNA methyltransferase (DNMT) inhibitors. The data emphasize the importance of patience in the use of these drugs, with several cycles required for the manifestations of hematologic responses. Improved survival in patients with high-risk myelodysplastic syndrome (MDS) treated with azacitidine extends to patients with any International Working Group-defined hematologic response; however, the benefit to patients with stable disease is less clear. A great deal remains to be learned about the optimal dosing and scheduling of the DNMT inhibitors, alone and in combination. New information on the impact of DNMT inhibitors on the immune system and on stem cells will likely lead to novel uses of these drugs in MDS and other hematologic and nonhematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.